Render Target: STATIC
Render Timestamp: 2024-11-15T09:51:00.559Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-20 06:19:03.897
Product last modified at: 2024-09-26T17:45:07.719Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159
  1. Products /
  2. Cytokines & Growth Factors /
  3. Human Vascular Endothelial Growth Factor-121 (hVEGF121 )

Human Vascular Endothelial Growth Factor-121 (hVEGF121 ) #8908

    Product Information

    Product Usage Information

    Reconstitution:

    With carrier: Add sterile PBS or PBS containing 1% bovine or human serum albumin or 5-10% FBS to a final hVEGF121 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.

    Carrier free: Add sterile PBS or PBS containing protein to minimize absorption of hVEGF121 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hVEGF121 should be greater than 50 μg/ml.

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hVEGF121. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 14-21
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hVEGF121. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1μg hVEGF121.
    Activity The bioactivity of recombinant hVEGF121 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 0.5-2 ng/ml.
    Molecular Formula Recombinant hVEGF121 contains no "tags" and the nonglycosylated protein has a calculated MW of 14,057. DTT-reduced protein migrates as a 14-22 kDa polypeptide. Heterogeneity in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 30-36 kDa protein. The expected amino-terminal APMAE of recombinant hVEGF121 was verified by amino acid sequencing.

    Source / Purification

    Recombinant human VEGF121 (hVEGF121) Ala207-Arg327 (Accession #NP_001020541.2) was expressed in human 293 cells at Cell Signaling Technology.

    Background

    VEGF121 is the second most abundant splice variant of VEGF-A (1,2). VEGF121 is produced by endothelial cells, macrophages, T-cells and other cell types. VEGF121 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1). VEGF121 expression is induced by hypoxia, inflammatory cytokines and through oncogene products in tumors (1-3). VEGF121 binds to VEGFR1 and VEGFR2 receptor tyrosine kinases (1). Binding of VEGF121 to VEGFR1 and VEGFR2 leads to activation of pathways involving PI3K/AKT, P38 MAPK, and FAK (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).

    Database Links

    UniProt ID: P15692-1


    Entrez-Gene Id: 7422


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.